Introduction to direct oral anticoagulants and rationale for specific reversal agents☆,☆☆,★
Bleeding with direct oral anticoagulants vs warfarin: clinical experience☆,☆☆,★
Safety of direct oral anticoagulants: insights from postmarketing studies☆,☆☆,★,★★
Discontinuation and management of direct-acting anticoagulants for emergency procedures☆,☆☆,★
Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed☆,☆☆,★
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects☆,☆☆,★
Evidence supporting idarucizumab for the reversal of dabigatran☆,☆☆,★
Preclinical and clinical data for factor Xa and “universal” reversal agents☆,☆☆,★
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols☆,☆☆,★